Cellular Origins launches Constellation, its configurable robotic platform for scalable manufacturing of advanced therapies

Cellular Origins launches Constellation, its configurable robotic platform for scalable manufacturing of advanced therapies

A closed, fully automated and configurable robotic platform for cell therapy manufacturing can increase space efficiency by 30 times and reduce production costs and labor by 51% and 16 times, respectively. The platform scales the manufacturing of cell therapies without changing the process used in clinical trials. The platform was launched at the ISCT Annual Meeting 2023.

Cellular Origins, a TTP company focused on enabling scalable, cost-effective, and space-efficient manufacturing of cell and gene therapies (CGTs), today announced the launch of Constellation™, its closed-loop, configurable robotic platform, at the International Society for Cell and Gene Therapy (ISCT) 2023 Annual Meeting. Constellation is designed to automate and combine manufacturing of advanced therapies without significant process redevelopment aseptic liquid handling technologies with advanced automation from the Industry 4.0 revolution.

Despite the therapeutic potential that CGTs offer and despite the rapid growth of the sector (over $90 billion by 2030, compound annual growth rate of 22%), these advanced therapies remain largely unavailable to patients worldwide due to a mismatch between therapeutic innovation and manufacturing capacity for affordable mass production. Cellular Origins' platform is capable of increasing space efficiency by 30x compared to traditional, manual techniques while reducing production costs and labor by 51% and 16x, respectively. It was designed to address this need and provide therapy developers with access to large-scale sterile manufacturing.

Constellation combines highly flexible, autonomous mobile robots, proprietary tube welding technology and automated tube management to enable sterile fluid transfer. These robots are connected to a fully configurable modular console system tailored to the needs of each individual therapy.

This combination provides a complete end-to-end digital connection, including quality control systems and full digital remote control and analysis. Cellular Origins works closely with a growing list of partners, such as the recently announced collaboration with ScaleReady, to ensure optimized integration with existing and future bioprocessing instruments at every production scale, from laboratory system to factory.

Dr. Edwin Stone, CEO of Cellular Origins, commented: "The increasing disconnect between biological innovation in advanced therapies and manufacturing capacity is one of the key issues preventing these types of life-saving therapies from coming to market. Cellular Origins' platform, Constellation, is designed to address this urgent need. Our configurable and automated robotic technology brings the Industry 4.0 revolution to the forefront of CGT, enabling efficient, scalable, automated production without new process development.”

Cellular Origins will present Constellation at booth #4 at ISCT 2023, May 31-June 3 in Paris.

For more information or to discuss how Cellular Origins can support your workflow in producing advanced therapies, please visit:

Sources: